Ipamorelin/Tesamorelin Blend 15mg
Pre-blended stack for comparative research work.
Pre-blended Ipamorelin + Tesamorelin research stack. Combines a ghrelin-receptor agonist (ipamorelin) with a stabilized GHRH analog (tesamorelin) for dual-pathway GH-axis research.
Proposed mechanism
Tesamorelin activates the GHRH receptor; ipamorelin activates the ghrelin receptor. Combined activation produces research-reported amplified GH release compared to either compound alone.
Research highlights
- Dual-pathway GH stack
- Stabilized GHRH analog + selective ghrelin agonist
- Co-lyophilized for single-reconstitution convenience
- Multiple ratio options across product variants
Research protocol notes
Reconstitute under sterile technique with bacteriostatic water. Typical volumes range from 1–3 mL depending on the target working concentration. Swirl gently — do not shake — to avoid peptide shearing.
Stacking and comparative studies
Pre-stacked — typically studied as-is.
Handling and storage
Lyophilized powder is stable at ambient shipping temperatures. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 28 days. For long-term storage of unreconstituted vials, freeze at −20 °C and protect from light.
Frequently asked
How does this differ from an Ipamorelin + CJC-1295 blend?
Tesamorelin is a more native-GHRH-like compound; CJC-1295 is an engineered longer-acting analog. The tesamorelin blend is closer to a "natural" GH-pulse research design.
What ratios are available?
Two formats: IPA 3mg + TESA 10mg, and IPA 5mg + TESA 10mg. Choose based on the target ratio for your research.
Is a COA provided per component?
Yes — identity and purity are verified independently for each component.
What is IPA/TESA?
Shorthand for ipamorelin (IPA) + tesamorelin (TESA).
